Prognostic value of serum albumin for long-term mortality in patients with dual-chamber permanent pacemakers

Biomark Med. 2022 Apr;16(5):341-348. doi: 10.2217/bmm-2021-0991. Epub 2022 Mar 2.

Abstract

Background: This investigation aims to examine the prognostic utility of albumin concentrations for long-term all-cause mortality in patients undergoing permanent pacemaker implantation. Methods: A total of 1798 patients who received permanent pacemaker implantation were divided into quartiles according to serum albumin concentrations. The significance of albumin in predicting long-term mortality was compared in these quartiles. Results: There was a higher rate of long-term mortality in the Q4 group compared with the Q1-3 groups (49.9 vs 15.8%). The risk of long-term mortality in the Q4 group was 3.6-times higher compared with the Q1-3 groups after adjustment for confounders. Conclusion: Serum albumin level at the time of device implantation has great value when assessing long-term mortality in patients with permanent pacemakers.

Keywords: albumin; dual-chamber pacemaker; long-term mortality; pacemaker.

MeSH terms

  • Humans
  • Pacemaker, Artificial* / adverse effects
  • Prognosis
  • Serum Albumin*

Substances

  • Serum Albumin